课题基金 / 基金详情

Developing Fisetin for the Managment of Prostate Cancer

Developing Fisetin for the Managment of Prostate Cancer
开发非瑟酮治疗前列腺癌
批准号:
8644570
负责人:
Hasan Mukhtar
金额:
$5.39万
依托单位国家:
美国
项目类别:
财政年份:
2011
资助国家:
美国
项目状态:
已结题
起止时间:
2011-07-01 至 2016-05-31

项目摘要

项目成果

Hasan Mukhtar的其他基金

相似基金

相关文献

中文摘要
翻译
前列腺癌是最常见的癌症,也是美国男性癌症相关死亡的第二大常见原因。尽管预防和治疗方面的进步提高了总体生存率,但显然仍然需要有效的基于机制的方法来实现前列腺癌管理的长期改善。在许多与前列腺癌的发展有关的信号网络中,有PTEN/AKT/哺乳动物雷帕霉素靶蛋白(AKT/mTOR)和MAPK途径。值得注意的是,PTEN/AKT/mTOR和MAPK信号通路协同作用,促进肿瘤生长和激素难治性疾病的出现。这些观察结果构成了我们提出的同时靶向PTEN/Akt/mTOR和MAPK信号通路可能是抑制前列腺上皮内瘤变(PIN)发展及其向癌症转化的有效策略的基础。根据这一假设,在我们追求无毒的化学预防膳食剂的过程中,我们最近对非瑟酮进行了一些新颖而令人兴奋的观察,非瑟酮是一种结构独特的化学物质,属于多酚类黄酮。用非西汀治疗前列腺癌PC3细胞可抑制mTOR激酶信号传导。利用一个独特的人类前列腺上皮细胞系家族,模拟前列腺癌发生过程中的多个步骤,我们观察到转化的细胞具有更高的肿瘤发生潜力,表现出更高的mTOR信号传导,对非瑟酮诱导的细胞死亡更敏感。更有趣的是,通过分子模型,我们观察到非瑟酮与mTOR分子发生物理相互作用,并在两个结合能为-8Kcal/mol的位点停靠。这些观察结果提供了证据,证明非瑟酮是一种新的mTOR信号复合物抑制剂,可诱导细胞死亡。在这项应用中,我们建议利用非塞酮靶向多种信号通路的能力,并在体外使用一个独特的6个人类前列腺上皮细胞家族和在体内使用基因工程Nkx3.1/Pten突变小鼠模型来研究其有效性,该模型再现了人类前列腺癌的许多特征。与当前研究最相关的是,Nkx3.1/Pten突变小鼠在癌症进展过程中表现出AKT/mTOR和MAPK信号的激活。因此,我们认为这些Nkx3.1/Pten小鼠应该提供一个很好的临床前模型来测试同时靶向AKT/mTOR和ERK MAPK信号对前列腺肿瘤发生的影响。在这个应用中,我们将1)建立PTEN/Akt/mTOR和MAPK信号通路的参与,并确定非瑟酮在一个独特的人类前列腺上皮细胞系家族中的功效,该家族模仿前列腺癌发生过程中的多个步骤;2)在Nkx3.1/ PTEN前列腺癌小鼠模型中研究膳食非瑟酮的作用以及PTEN/Akt/mTOR和MAPK信号通路在PIN和雄激素依赖性腺癌发展中的作用;3)在Nkx3.1/ PTEN突变晚期前列腺癌小鼠模型中研究非瑟酮对去势诱导的雄激素非依赖型腺癌的作用。这一建议的成功完成可能会导致非瑟酮作为一种预防和治疗前列腺癌的新型药物的发展。
英文摘要
Prostate cancer is the most commonly diagnosed cancer and the second most common cause of cancer related deaths among men in the US. Although advances in prevention and treatment have improved overall survival, there remains a clear need for effective mechanism-based approaches that can achieve long-term improvements in the management prostate cancer. Among the many signaling networks that have been implicated in the development of prostate cancer are the PTEN/AKT/mammalian target of rapamycin (AKT/mTOR) and MAPK pathways. Notably, the PTEN/AKT/mTOR and MAPK signaling pathways function cooperatively to promote tumor growth and the emergence of hormone-refractory disease. These observations form the basis of our proposal that simultaneous targeting of the PTEN/Akt/mTOR and the MAPK signaling pathways may be an effective strategy for inhibiting the development of prostatic intraepithelial neoplasia (PIN) and its conversion to cancer. In line with this hypothesis and in our pursuit for non-toxic dietary agents for chemoprevention, we recently made some novel and exciting observations with fisetin, a structurally distinct chemical substance that belongs to the flavonoid group of polyphenols. Treatment of prostate cancer PC3 cells with fisetin resulted in inhibition of mTOR kinase signaling. Using a unique family of human prostate epithelial cell lines that mimic multiple steps in the process of prostate carcinogenesis we observed that transformed cells with increased potential for tumorigenesis exhibit higher mTOR signaling and greater sensitivity to fisetin induced cell death. More interestingly, using molecular modeling we observed that fisetin physically interacts with the mTOR molecule and docks at two sites with a binding energy of -8Kcal/mol. These observations provide evidence that fisetin functions as a novel inhibitor of mTOR signaling complex leading to induction of cell death. In this application we propose to take advantage of fisetin's ability to target multiple signaling pathways and investigate its efficacy in vitro using a unique family of six human prostate epithelial cells and in vivo using a genetically engineered Nkx3.1/Pten mutant mouse model that recapitulates many features of human prostate cancer. Most relevant for the current study, Nkx3.1/Pten mutant mice display activation of AKT/mTOR and MAPK signaling during cancer progression. Therefore, we reasoned that these Nkx3.1/Pten mice should provide an excellent preclinical model to test the consequences of simultaneous targeting of AKT/mTOR and ERK MAPK signaling for prostate tumorigenesis. In this application we will 1) establish the involvement of PTEN/Akt/mTOR and the MAPK signaling pathways and determine the efficacy of fisetin in a unique family of human prostate epithelial cell lines that mimic multiple steps in the process of prostate carcinogenesis, 2) investigate the effects of dietary fisetin and involvement of PTEN/Akt/mTOR and the MAPK signaling pathways during the development of PIN and androgen dependent adenocarcinoma in the Nkx3.1/Pten mouse model of prostate cancer and 3) investigate the efficacy of fisetin against castration induced androgen independent adenocarcinoma in the Nkx3.1/Pten mutant mouse model of advanced prostate cancer. A successful completion of this proposal may result in the development of fisetin as a novel agent for prevention and possibly for the treatment of prostate cancer.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Defining the role of miR-30 in human skin
  • 批准号:
    8813976
  • 项目类别:
  • 资助金额:
    $19.87万
  • 财政年份:
    2014
  • 负责人:
    Hasan Mukhtar
  • 依托单位:
Defining the role of miR-30 in human skin
  • 批准号:
    8923147
  • 项目类别:
  • 资助金额:
    $16.56万
  • 财政年份:
    2014
  • 负责人:
    Hasan Mukhtar
  • 依托单位:
Developing Fisetin for the Managment of Prostate Cancer
  • 批准号:
    8278499
  • 项目类别:
  • 资助金额:
    $30.81万
  • 财政年份:
    2011
  • 负责人:
    Hasan Mukhtar
  • 依托单位:
Developing Fisetin for the Managment of Prostate Cancer
  • 批准号:
    8160855
  • 项目类别:
  • 资助金额:
    $30.81万
  • 财政年份:
    2011
  • 负责人:
    Hasan Mukhtar
  • 依托单位:
国内基金
海外基金
大肠癌发生机制的adenoma-adenocarcinoma pathway同serrated pathway的关系的研究
  • 批准号:
    30840003
  • 项目类别:
    专项基金项目
  • 资助金额:
    12.0万元
  • 批准年份:
    2008
  • 负责人:
    焦宇飞
  • 依托单位: